Thursday, October 3, 2013
Publication and contact
Protein phosphatase 2 (PPP2CA; PP2A)
Studies in patient samples
and mice suggest Gilenya fingolimod and
nonimmunosuppressive derivatives could help eradicate leukemic stem cells in
CML, which are associated with disease relapse. In leukemic hematopoietic
stem cells (HSCs) isolated from patients with CML, PP2A activity was lower
than that in healthy HSCs. In the CML stem cells, Gilenya or any of three
nonimmunosuppressive derivatives activated PP2A, impaired self-renewal and
induced apoptosis. In mouse xenograft models of CML, Gilenya decreased
leukemic stem cell numbers compared with no treatment. Next steps include
designing additional PP2A activators.
Novartis AG markets the sphingosine 1-phosphate receptor
agonist Gilenya to treat relapsing forms of multiple sclerosis (MS).
Oncotide Pharmaceuticals Inc.
has SET nuclear oncogene (SET)
inhibitors in preclinical development to treat various cancers. SET
inhibition is designed to activate PP2A.
Published online Oct. 3, 2013
Multiple patent applications
filed covering nonimmunosuppressive derivatives and their use in various cancers;
available for licensing and partnering from The Ohio State
Technology Commercialization and Knowledge Transfer Office
Neviani, P. et al. J.
Clin. Invest.; published online Sept. 3, 2013;
Contact: Danilo Perrotti, University of Maryland, College
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]